Assessment of immunosuppressive activity of human mesenchymal stem cells using murine antigen specific CD4 and CD8 T cells in vitro

Stem Cell Research and Therapy

Volumn 4, Issue 5, 2013, Pages

  Nazarov, Cristina ^a   Surdo, Jessica Lo ^a   Bauer, Steven R ^a   Wei, Cheng Hong ^a,b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD69 ANTIGEN; COGNATE PEPTIDE ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; MESSENGER RNA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SURFACE; COCULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE ACTIVITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

MURINAE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL;

EID: 84886871106     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt339     Document Type: Article

References (49)

1. Multilineage potential of adult human mesenchymal stem cells. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR, Science 1999 284 143 147 10.1126/science.284.5411.143 10102814 (Pubitemid 29282067)
2. Trafficking and differentiation of mesenchymal stem cells. Liu ZJ, Zhuge Y, Velazquez OC, J Cell Biochem 2009 106 984 991 10.1002/jcb.22091 19229871
3. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M, Arthritis Rheum 2009 60 1006 1019 10.1002/art.24405 19333946
4. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
5. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Delorme B, Ringe J, Pontikoglou C, Gaillard J, Langonne A, Sensebe L, Noel D, Jorgensen C, Haupl T, Charbord P, Stem Cells 2009 27 1142 1151 10.1002/stem.34 19418444
6. Therapeutic potential of bone-marrow-derived mesenchymal stem cells differentiated with growth-factor-free coculture method in liver-injured rats. Li TZ, Kim JH, Cho HH, Lee HS, Kim KS, Lee SW, Suh H, Tissue Eng Part A 2010 16 2649 2659 10.1089/ten.tea.2009.0814 20367252
7. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG, Proc Natl Acad Sci U S A 2007 104 11002 11007 10.1073/pnas.0704421104 17569781 (Pubitemid 47175216)
8. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK, Nat Med 1999 5 309 313 10.1038/6529 10086387 (Pubitemid 29124367)
9. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R, Exp Hematol 2002 30 42 48 10.1016/S0301-472X(01)00769-X 11823036 (Pubitemid 34059216)
10. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM, Blood 2002 99 3838 3843 10.1182/blood.V99.10.3838 11986244 (Pubitemid 34534559)
11. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F, Blood 2003 101 3722 3729 10.1182/blood-2002-07-2104 12506037 (Pubitemid 36857965)
12. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O, Exp Hematol 2003 31 890 896 10.1016/S0301-472X(03) 00110-3 14550804 (Pubitemid 37211373)
13. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F, Blood 2005 105 2821 2827 10.1182/blood-2004-09-3696 15591115 (Pubitemid 40446275)
14. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Prockop DJ, Mol Ther 2009 17 939 946 10.1038/mt.2009.62 19337235
15. ClinicalTrials.gov: a service of the U.S. National Institutes of Health. http://www.clinicaltrials.gov/
16. Mesenchymal stem cells: mechanisms of inflammation. Singer NG, Caplan AI, Annu Rev Pathol 2011 6 457 478 10.1146/annurev-pathol-011110-130230 21073342
17. Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT): Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Krampera M, Galipeau J, Shi Y, Tarte K, Cytotherapy 2013 15 1054 1061 10.1016/j.jcyt.2013.02.010 23602578
18. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ, Proc Natl Acad Sci U S A 2006 103 17438 17443 10.1073/pnas.0608249103 17088535 (Pubitemid 44788987)
19. Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. Li J, Ezzelarab MB, Cooper DK, Xenotransplantation 2012 19 273 285 10.1111/xen.12000 22978461
20. T-lymphocyte clone specific for pancreatic islet antigen. Haskins K, Portas M, Bradley B, Wegmann D, Lafferty K, Diabetes 1988 37 1444 1448 10.2337/diab.37.10.1444 2458291 (Pubitemid 19035999)
21. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, Serreze DV, Shabanowitz J, Hunt DF, Nathenson SG, Santamaria P, DiLorenzo TP, Proc Natl Acad Sci U S A 2003 100 8384 8388 10.1073/pnas.0932778100 12815107 (Pubitemid 36842554)
22. Quantitative approaches to detect donor and passage differences in adipogenic potential and clonogenicity in human bone marrow-derived mesenchymal stem cells. Lo Surdo J, Bauer SR, Tissue Eng Part C Methods 2012 18 877 889 10.1089/ten.tec.2011.0736 22563812
23. The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Gronthos S, Graves SE, Ohta S, Simmons PJ, Blood 1994 84 4164 4173 7994030 (Pubitemid 24371919)
24. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Zheng ZH, Li XY, Ding J, Jia JF, Zhu P, Rheumatology (Oxford) 2008 47 22 30 10.1093/rheumatology/kem284 18077486 (Pubitemid 350286256)
25. Human mesenchymal stem cells modulate B-cell functions. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A, Blood 2006 107 367 372 10.1182/blood-2005- 07-2657 16141348 (Pubitemid 43053565)
26. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH, Glia 2009 57 1192 1203 10.1002/glia.20841 19191336
27. Immunosuppressive properties of mesenchymal stem cells. Abumaree M, Al Jumah M, Pace RA, Kalionis B, Stem Cell Rev 2012 8 375 392 10.1007/s12015-011- 9312-0 21892603
28. Human foreskin fibroblasts exert immunomodulatory properties by a different mechanism to bone marrow stromal/stem cells. Wada N, Bartold PM, Gronthos S, Stem Cells Dev 2011 20 647 659 10.1089/scd.2010.0246 20712449
29. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Zhao S, Wehner R, Bornhauser M, Wassmuth R, Bachmann M, Schmitz M, Stem Cells Dev 2010 19 607 614 10.1089/scd.2009.0345 19824807
30. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F, Stem Cells 2006 24 386 398 10.1634/stemcells.2005-0008 16123384 (Pubitemid 44464808)
31. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Berman DM, Willman MA, Han D, Kleiner G, Kenyon NM, Cabrera O, Karl JA, Wiseman RW, O'Connor DH, Bartholomew AM, Kenyon NS, Diabetes 2010 59 2558 2568 10.2337/db10-0136 20622174
32. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y, Biol Blood Marrow Transplant 2010 16 838 847 10.1016/j.bbmt.2010.01.011 20109568
33. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Toubai T, Paczesny S, Shono Y, Tanaka J, Lowler KP, Malter CT, Kasai M, Imamura M, Curr Stem Cell Res Ther 2009 4 252 259 10.2174/157488809789649269 19500066
34. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L, Cell Mol Immunol 2008 5 417 424 10.1038/cmi.2008.52 19118507
35. Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats. Omori Y, Honmou O, Harada K, Suzuki J, Houkin K, Kocsis JD, Brain Res 2008 1236 30 38 18722359
36. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD, J Cereb Blood Flow Metab 2008 28 329 340 10.1038/sj.jcbfm.9600527 17637706 (Pubitemid 351161284)
37. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, Murphy K, O'Garra A, J Exp Med 1996 183 901 913 10.1084/jem.183.3.901 8642294 (Pubitemid 26114795)
38. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. Feili-Hariri M, Falkner DH, Morel PA, J Leukoc Biol 2005 78 656 664 10.1189/jlb.1104631 15961574 (Pubitemid 41292088)
39. Transcriptional regulation of GATA3 in T helper cells by the integrated activities of transcription factors downstream of the interleukin-4 receptor and T cell receptor. Scheinman EJ, Avni O, J Biol Chem 2009 284 3037 3048 19056736
40. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Hernandez-Hoyos G, Anderson MK, Wang C, Rothenberg EV, Alberola-Ila J, Immunity 2003 19 83 94 10.1016/S1074-7613(03)00176-6 12871641 (Pubitemid 36859903)
41. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G, Eur J Immunol 2005 35 1482 1490 10.1002/eji.200425405 15827960 (Pubitemid 40691430)
42. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D, Blood 2004 103 4619 4621 10.1182/blood-2003-11-3909 15001472 (Pubitemid 38745993)
43. Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF, Blood 2005 105 1815 1822 10.1182/blood-2004-04-1559 15494428 (Pubitemid 40223708)
44. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K, Blood 2007 109 228 234 10.1182/blood-2006-02-002246 16985180 (Pubitemid 46053063)
45. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, Anegon I, Cuturi MC, Blood 2007 110 3691 3694 10.1182/blood-2007-02-075481 17684157 (Pubitemid 350159638)
46. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Gieseke F, Schutt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Muller I, Blood 2007 110 2197 2200 10.1182/blood-2007-04-083162 17522338 (Pubitemid 47443941)
47. Mesenchymal stem cells induce apoptosis of activated T cells. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC, Leukemia 2005 19 1597 1604 10.1038/sj.leu.2403871 16049516 (Pubitemid 43090404)
48. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, Yen BL, Stem Cells 2006 24 2466 2477 10.1634/stemcells.2006-0071 17071860 (Pubitemid 44674307)
49. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R, J Immunol 2009 183 993 1004 10.4049/jimmunol.0900803 19561093